Molecular Testing and Personalized Medicine Transform Breast Cancer Care
Molecular testing and liquid biopsies are revolutionizing breast cancer treatment by identifying genetic mutations and enabling personalized, targeted therapies for patients.
Molecular testing and personalized medicine are transforming breast cancer treatment by shifting the focus from general categorization to understanding the unique biological fingerprint of each tumor. While traditional metrics such as tumor size, location, and hormone receptor status remain foundational, modern oncology seeks to identify the specific genetic mutations driving cancer growth.
The Role of Genetic Mutations
Two patients with identical baseline diagnoses can exhibit vastly different biological behaviors and treatment responses. Advanced molecular profiling allows clinicians to detect actionable mutations that dictate how a tumor behaves. For instance, mutations in the PIK3CA gene lead to the overactivation of the PI3K pathway, which governs cell division and survival. Identifying this alteration in hormone receptor-positive, HER2-negative advanced breast cancer opens the door to targeted therapies specifically designed to inhibit this mechanism.
Similarly, mutations in the BRCA1 and BRCA2 genes impair cellular DNA repair capabilities, creating specific vulnerabilities that targeted drugs can exploit. Furthermore, cancer is not static; tumors frequently evolve during treatment. An ESR1 gene mutation, for example, can emerge over time and confer resistance to standard anti-hormonal therapies, enabling the disease to progress.
Liquid Biopsy and Real-Time Monitoring
To track these dynamic changes without invasive procedures, oncologists increasingly rely on liquid biopsies. By analyzing circulating tumor DNA (ctDNA) in a simple blood sample, physicians gain real-time insight into the tumor's evolving genetic landscape. This capability allows medical teams to detect newly acquired resistance mechanisms and adjust therapeutic strategies accordingly.
Ultimately, personalized oncology aims to deliver the right treatment to the right patient at the right time. As Prof. Amir Sonnenblick, head of the Breast Cancer Unit at the Tel Aviv Sourasky Medical Center (Ichilov), notes, molecular diagnostics are not applied simply because technology permits, but to secure actionable data that fundamentally enhances patient outcomes.
